This report takes a deep dive into two areas impacting the success of these studies: recruitment and retention. Given the importance of each rare disease patient, these activities are time-intensive and resource-heavy.

ISR surveyed 100 decision-makers in the pharmacovigilance space to get insight on their experience regarding how their companies’ pharmacovigilance activities are split between processes, how much of their work is outsourced, and both in-house and outsourced personnel locations.

For this report, ISR surveyed 111 respondents regarding their insights on topics such as Central IRB selection, outsourcing trends, use, and perceptions of Central IRBs. Furthermore, recent users of 18 Central IRBs rated how well performance compared against their expectations on 21 attributes across four categories (Organization Factors, Capabilities, Submission and Review, and Study Management).

This report includes verbatim insights into the practices that create clinical site start up efficiency, the causes of inefficiency, and new practices being undertaken in an effort to improve efficiency. To get multiple perspectives on the site start up process, ISR surveyed people with site start up responsibilities at sponsors and CROs as well as people working at clinical sites, such as clinical investigators and study coordinators.

A Study Trends and Market Outlook report aims at providing our readers with a high-level view of the clinical development space. The data for this market research report comes from 137 Phase I decision-makers who were surveyed to share their insights.

This market research report will provide readers with a high-level view of the clinical development space. 139 Phase II/III decision-makers were surveyed to share their insights into where the Phase II/III market is now and where it’s expected to head over the next four years.

The goal of this market research report is to provide readers with a high-level view of the clinical development space. 115 Late Phase decision-makers were surveyed to share their insights into where the Late Phase market is now and where it’s expected to head over the next four years.

This report gives quantitative insight into the perpetual question: “What is the size of the CRO market?” The data provide a thorough, rational perspective for clinical development services segmented by phase, geography, and service line.

Ask any HR manager working at a CRO or sponsor organization and they will tell you there is a war for talent when it comes to hiring and retaining high-quality CRAs. ISR decided to take a deep look at not only CRA salaries, but also signing bonuses, retention bonuses, raises, and turnover with the aim of benchmarking some industry trends. We collected data from 227 CRAs from various organizations and...

This market research report takes a look at user experiences with seven different clinical development outsourcing models.

This report will help both study sponsors and providers answer a number of questions relevant to selecting and evaluating central lab service providers. For the purpose of this report, “central lab” is defined as a vendor that supplies specimen collection kits, logistics services, safety alerts, and a wide variety of laboratory testing services as well as providing lab reports to investigators.

This report provides an overview of the current market dynamics in the clinical manufacturing space as well as an outlook of what our survey respondents predict the marketplace will look like in 2022.

For this report, ISR surveyed 109 respondents at sponsors and CROs regarding their experiences with hybrid trials and the providers of these services.

This report offers insight on CRO selection and CRO performance based off of data from 191 experienced Phase I outsourcers and more than 500 service provider encounters.

This research will help small and emerging biopharma companies make more informed CRO selection decisions. These findings will also help CROs optimize operational and marketing strategies to better accommodate this segment.

The goal of this market research report is to provide detailed information to aid in making informed decisions when outsourcing Phase IV work. You can purchase a single-user license for individual use, a site-wide license giving access to the report for all employees within a single site/office location, or an enterprise-wide license giving access...

Sponsors can use this report to evaluate their lab selection process. Bioanalytical labs can use it to learn how their company performs against competitors. Topics covered include lab selection and perceptions, lab performance, and lab service quality profiles.

This report is a resource for sponsor companies looking for information on CRO selection and performance. It includes insights from 237 Phase II/III outsourcers with over 800 service encounters.

Study sponsors and CROs can use this report for insight into user experience/satisfaction with leading eTMF software providers to inform their vendor selection process, and eTMF providers can use it to better understand their own strengths and weaknesses - and those of their competitors.

For this study, Industry Standard Research (ISR) collected both qualitative and quantitative data. Qualitative telephone interviews were used to gain insight into mHealth expert viewpoints, while a quantitative, internet-based survey was used to collect hard data on familiarity with mHealth, anticipated implementation, and usage rates in recent or soon-to-be conducted clinical trials.

This market research report covers the state of the IRT and its apparent transition from standalone point products to more fully integrated systems that use and feed data into other eClinical systems such as EDC systems, CTMS, and eCOA systems, in addition to managing randomization and drug supply functions.

This market research report examines the industry perception of the EDC market based on the responses of 132 industry professionals experienced with these systems. ISR has asked respondents how their respective companies handle the decisions associated with outsourcing these systems as well as how they would prefer the outsourcing be...

For this report, ISR surveyed 110 qualified CTMS decision-makers regarding their insights on topics such as CTMS selection drivers, outsourcing trends, use, and perceptions of providers. Respondents also shared general improvements they would like to see in the next generation of CTMS software and conveyed provider-specific...

Technology forges a world where human connection is no longer inhibited by distance. Barriers are broken and replaced with virtual bridges that create unprecedented potential for an interconnected present and future. And no doubt the areas most affected by this technological nexus are ones dominated by human synergy. An area at...

ISR conducted 11 in-depth interviews with tenured post-marketing safety and pharmacovigilance professionals from leading biotechnology and pharmaceutical companies in North America and Europe.

For this report, ISR conducted interviews with a cross-section of executive, director, and managerial level MM professionals from large, mid-size, and small pharmaceutical and biotech companies to gain a better understanding of managed markets departments, how they work, and the challenges they face.

This market research report has been designed to be used as a benchmarking tool for companies to compare their Medical Science Liaison functions to those of other pharmaceutical and biotech organizations. You can purchase a single-user license for individual use, a site-wide license giving access to the report for all employees within...